Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Role of Drug Delivery System in Improving the Bioavailability of Resveratrol

Author(s): Zonish Saleem, Kanwal Rehman and Muhammad Sajid Hamid Akash*

Volume 28, Issue 20, 2022

Published on: 05 July, 2022

Page: [1632 - 1642] Pages: 11

DOI: 10.2174/1381612828666220705113514

Price: $65

Abstract

Resveratrol (RSV) is a natural polyphenolic compound known for its therapeutic activities but has limited bioavailability. The aim of our study was to explore various drug-delivering methods that are being employed to achieve target-oriented delivery and therapeutic performance of RSV. To improve the bioavailability and pharmacokinetic properties of RSV, efforts are being made to produce efficient formulations accompanying efficient drug delivery strategies. Several clinical trial studies have been conducted on RSV isomers, and the majority of studies indicated that trans-RSV had better clinical potential and therapeutic effectiveness in various types of complications such as colorectal cancer, metabolic syndrome, hypertension, obesity, neurodegenerative diseases, diabetes, hepatic disease, cardiac disorders, and breast cancer. However, multiple research studies enable us to understand various strategies that can enhance the systemic availability and efficacy of topical RSV formulations. In this article, we emphasize the hurdles of RSV delivery processes. We summarized that the micro- particulate system works efficiently for delivering liquid and solid microparticles of RSV. Another technique in which a coating encloses particles is called microencapsulation. This technique reduces the degradation of pharmaceutical compounds. Similarly, the cyclodextrin system is mainly used for poorly soluble drugs. On the other hand, the vesicular system is another micro-particulate system that can encapsulate hydrophilic and hydrophobic drugs. However, the RSV nanosponge formulations have advanced nano drug delivery systems, making it possible to use RSV for its antioxidant potential.

Keywords: Resveratrol, target-oriented, clinical trials, bioavailability, safety, delivery systems, therapeutic activity.

« Previous Next »
[1]
Hu M, Ge X, Chen X, Mao W, Qian X, Yuan WE. Micro/nanorobot: A promising targeted drug delivery system. Pharmaceutics 2020; 12(7): 665.
[http://dx.doi.org/10.3390/pharmaceutics12070665] [PMID: 32679772]
[2]
Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: What formulation solutions to bioavailability limitations? J Control Release 2012; 158(2): 182-93.
[http://dx.doi.org/10.1016/j.jconrel.2011.09.083] [PMID: 21978644]
[3]
De Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. Sulphation of resveratrol, a natural compound present in wine, and its inhibi-tion by natural flavonoids. Xenobiotica 2000; 30(9): 857-66.
[http://dx.doi.org/10.1080/004982500433282] [PMID: 11055264]
[4]
Frémont L. Biological effects of resveratrol. Life Sci 2000; 66(8): 663-73.
[http://dx.doi.org/10.1016/S0024-3205(99)00410-5] [PMID: 10680575]
[5]
Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res 2004; 24(5A): 2783-840.
[PMID: 15517885]
[6]
Hou C-Y, Tain YL, Yu HR, Huang LT. The effects of resveratrol in the treatment of metabolic syndrome. Int J Mol Sci 2019; 20(3): 535.
[http://dx.doi.org/10.3390/ijms20030535] [PMID: 30695995]
[7]
Cucciolla V, Borriello A, Oliva A, Galletti P, Zappia V, Della Ragione F. Resveratrol: From basic science to the clinic. Cell Cycle 2007; 6(20): 2495-510.
[http://dx.doi.org/10.4161/cc.6.20.4815] [PMID: 17726376]
[8]
Shah A, Reyes LM, Morton JS, Fung D, Schneider J, Davidge ST. Effect of resveratrol on metabolic and cardiovascular function in male and female adult offspring exposed to prenatal hypoxia and a high-fat diet. J Physiol 2016; 594(5): 1465-82.
[http://dx.doi.org/10.1113/JP271133] [PMID: 26467260]
[9]
Johnson JJ, Nihal M, Siddiqui IA, et al. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol Nutr Food Res 2011; 55(8): 1169-76.
[http://dx.doi.org/10.1002/mnfr.201100117] [PMID: 21714124]
[10]
Baur JA, Sinclair DA. Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov 2006; 5(6): 493-506.
[http://dx.doi.org/10.1038/nrd2060] [PMID: 16732220]
[11]
Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32(12): 1377-82.
[http://dx.doi.org/10.1124/dmd.104.000885] [PMID: 15333514]
[12]
Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 2005; 49(5): 472-81.
[http://dx.doi.org/10.1002/mnfr.200500010] [PMID: 15779070]
[13]
Kristl J, Teskac K, Caddeo C. Abramović; Z, Sentjurc M. Improvements of cellular stress response on resveratrol in liposomes. Eur J Pharm Biopharm 2009; 73(2): 253-9.
[http://dx.doi.org/10.1016/j.ejpb.2009.06.006] [PMID: 19527785]
[14]
Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12(3): 413-20.
[http://dx.doi.org/10.1023/A:1016212804288] [PMID: 7617530]
[15]
Fulda S. Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov 2010; 15(17-18): 757-65.
[http://dx.doi.org/10.1016/j.drudis.2010.07.005] [PMID: 20692359]
[16]
Rius C, Abu-Taha M, Hermenegildo C, et al. Trans- but not cis-resveratrol impairs angiotensin-II-mediated vascular inflammation through inhibition of NF-κB activation and peroxisome proliferator-activated receptor-gamma upregulation. J Immunol 2010; 185(6): 3718-27.
[http://dx.doi.org/10.4049/jimmunol.1001043] [PMID: 20709957]
[17]
Mérillon J-M, Fauconneau B, Teguo PW, Barrier L, Vercauteren J, Huguet F. Antioxidant activity of the stilbene astringin, newly extract-ed from Vitis vinifera cell cultures. Clin Chem 1997; 43(6 Pt 1): 1092-3.
[http://dx.doi.org/10.1093/clinchem/43.6.1092] [PMID: 9191572]
[18]
Basly J-P, Marre-Fournier F, Le Bail JC, Habrioux G, Chulia AJ. Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci 2000; 66(9): 769-77.
[http://dx.doi.org/10.1016/S0024-3205(99)00650-5] [PMID: 10698352]
[19]
Chen X, He H, Wang G, et al. Stereospecific determination of cis- and trans-resveratrol in rat plasma by HPLC: Application to pharma-cokinetic studies. Biomed Chromatogr 2007; 21(3): 257-65.
[http://dx.doi.org/10.1002/bmc.747] [PMID: 17294509]
[20]
Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci 2011; 1215(1): 9-15.
[http://dx.doi.org/10.1111/j.1749-6632.2010.05842.x] [PMID: 21261636]
[21]
Andlauer W, Kolb J, Siebert K, Fürst P. Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drugs Exp Clin Res 2000; 26(2): 47-55.
[PMID: 10894555]
[22]
Almeida L, Vaz-da-Silva M, Falcão A, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 2009; 53(S1): S7-S15.
[http://dx.doi.org/10.1002/mnfr.200800177] [PMID: 19194969]
[23]
Das S, Lin HS, Ho PC, Ng KY. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res 2008; 25(11): 2593-600.
[http://dx.doi.org/10.1007/s11095-008-9677-1] [PMID: 18629618]
[24]
Boocock DJ, Faust GE, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007; 16(6): 1246-52.
[http://dx.doi.org/10.1158/1055-9965.EPI-07-0022] [PMID: 17548692]
[25]
Kaldas MI, Walle UK, Walle T. Resveratrol transport and metabolism by human intestinal Caco-2 cells. J Pharm Pharmacol 2003; 55(3): 307-12.
[http://dx.doi.org/10.1211/002235702612] [PMID: 12724035]
[26]
Klingenberg M. Pigments of rat liver microsomes. Arch Biochem Biophys 2003; 409(1): 376-86.
[http://dx.doi.org/10.1016/S0003-9861(02)00621-5]
[27]
Lançon A, Delmas D, Osman H, Thénot JP, Jannin B, Latruffe N. Human hepatic cell uptake of resveratrol: Involvement of both passive diffusion and carrier-mediated process. Biochem Biophys Res Commun 2004; 316(4): 1132-7.
[http://dx.doi.org/10.1016/j.bbrc.2004.02.164] [PMID: 15044102]
[28]
De Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. Xenobiotica 2000; 30(6): 609-17.
[http://dx.doi.org/10.1080/004982500406435] [PMID: 10923862]
[29]
Azorín-Ortuño M, Yañéz-Gascón MJ, Pallarés FJ, et al. Pharmacokinetic study of trans-resveratrol in adult pigs. J Agric Food Chem 2010; 58(20): 11165-71.
[http://dx.doi.org/10.1021/jf102799m] [PMID: 20886884]
[30]
Burkon A, Somoza V. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides - two novel resveratrol metabolites in human plasma. Mol Nutr Food Res 2008; 52(5): 549-57.
[http://dx.doi.org/10.1002/mnfr.200700290] [PMID: 18435437]
[31]
Soleas GJ, Angelini M, Grass L, Diamandis EP, Goldberg DM. Absorption of trans-resveratrol in rats. Methods Enzymol 2001; 335: 145-54.
[http://dx.doi.org/10.1016/S0076-6879(01)35239-4] [PMID: 11400363]
[32]
Yu C, Shin YG, Chow A, et al. Human, rat, and mouse metabolism of resveratrol. Pharm Res 2002; 19(12): 1907-14.
[http://dx.doi.org/10.1023/A:1021414129280] [PMID: 12523673]
[33]
Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 2003; 36(1): 79-87.
[http://dx.doi.org/10.1016/S0009-9120(02)00397-1] [PMID: 12554065]
[34]
Rotches-Ribalta M, Andres-Lacueva C, Estruch R, Escribano E, Urpi-Sarda M. Pharmacokinetics of resveratrol metabolic profile in healthy humans after moderate consumption of red wine and grape extract tablets. Pharmacol Res 2012; 66(5): 375-82.
[http://dx.doi.org/10.1016/j.phrs.2012.08.001] [PMID: 22906730]
[35]
Pangeni R, Sahni JK, Ali J, Sharma S, Baboota S. Resveratrol: Review on therapeutic potential and recent advances in drug delivery. Expert Opin Drug Deliv 2014; 11(8): 1285-98.
[http://dx.doi.org/10.1517/17425247.2014.919253] [PMID: 24830814]
[36]
Ruivo J, Francisco C, Oliveira R, Figueiras A. The main potentialities of resveratrol for drug delivery systems. Braz J Pharm Sci 2015; 51(3): 499-513.
[http://dx.doi.org/10.1590/S1984-82502015000300002]
[37]
Augustin MA, Abeywardena MY, Patten G, et al. Effects of microencapsulation on the gastrointestinal transit and tissue distribution of a bioactive mixture of fish oil, tributyrin and resveratrol. J Funct Foods 2011; 3(1): 25-37.
[http://dx.doi.org/10.1016/j.jff.2011.01.003]
[38]
Annunziata G, Jiménez-García M, Capó X, et al. Microencapsulation as a tool to counteract the typical low bioavailability of polyphenols in the management of diabetes. Food Chem Toxicol 2020; 139: 111248.
[http://dx.doi.org/10.1016/j.fct.2020.111248] [PMID: 32156568]
[39]
Mendes JBE, Riekes MK, de Oliveira VM, et al. PHBV/PCL microparticles for controlled release of resveratrol: Physicochemical charac-terization, antioxidant potential, and effect on hemolysis of human erythrocytes. ScientificWorldJournal 2012; 2012: 542937.
[http://dx.doi.org/10.1100/2012/542937] [PMID: 22666135]
[40]
Das S, Ng K-Y, Ho PC. Design of a pectin-based microparticle formulation using zinc ions as the cross-linking agent and glutaraldehyde as the hardening agent for colonic-specific delivery of resveratrol: In vitro and in vivo evaluations. J Drug Target 2011; 19(6): 446-57.
[http://dx.doi.org/10.3109/1061186X.2010.504272] [PMID: 20684731]
[41]
Suktham K, Koobkokkruad T, Wutikhun T, Surassmo S. Efficiency of resveratrol-loaded sericin nanoparticles: Promising bionanocarri-ers for drug delivery. Int J Pharm 2018; 537(1-2): 48-56.
[http://dx.doi.org/10.1016/j.ijpharm.2017.12.015] [PMID: 29229512]
[42]
Jacob S, Nair AB. Cyclodextrin complexes: Perspective from drug delivery and formulation. Drug Dev Res 2018; 79(5): 201-17.
[http://dx.doi.org/10.1002/ddr.21452] [PMID: 30188584]
[43]
Ansari KA, Vavia PR, Trotta F, Cavalli R. Cyclodextrin-based nanosponges for delivery of resveratrol: In vitro characterisation, stability, cytotoxicity and permeation study. AAPS PharmSciTech 2011; 12(1): 279-86.
[http://dx.doi.org/10.1208/s12249-011-9584-3] [PMID: 21240574]
[44]
Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian J Pharm Sci 2009; 71(4): 349-58.
[http://dx.doi.org/10.4103/0250-474X.57282] [PMID: 20502539]
[45]
Teskač K, Kristl J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm 2010; 390(1): 61-9.
[http://dx.doi.org/10.1016/j.ijpharm.2009.10.011] [PMID: 19833178]
[46]
Singh G, Pai RS. In-vitro/in-vivo characterization of trans-resveratrol-loaded nanoparticulate drug delivery system for oral administration. J Pharm Pharmacol 2014; 66(8): 1062-76.
[http://dx.doi.org/10.1111/jphp.12232] [PMID: 24779896]
[47]
Sinico C, Pireddu R, Pini E, et al. Enhancing topical delivery of resveratrol through a nanosizing approach. Planta Med 2017; 83(5): 476-81.
[PMID: 27220078]
[48]
Kobierski S, Ofori-Kwakye K, Müller RH, Keck CM. Resveratrol nanosuspensions: Interaction of preservatives with nanocrystal pro-duction. Pharmazie 2011; 66(12): 942-7.
[PMID: 22312699]
[49]
Liu Q, Guan J, Sun Z, et al. Influence of stabilizer type and concentration on the lung deposition and retention of resveratrol nanosus-pension-in-microparticles. Int J Pharm 2019; 569: 118562.
[http://dx.doi.org/10.1016/j.ijpharm.2019.118562] [PMID: 31351178]
[50]
Zulueta A, Caretti A, Signorelli P, Ghidoni R. Resveratrol: A potential challenger against gastric cancer. World J Gastroenterol 2015; 21(37): 10636-43.
[http://dx.doi.org/10.3748/wjg.v21.i37.10636] [PMID: 26457023]
[51]
Elshaer M, Chen Y, Wang XJ, Tang X. Resveratrol: An overview of its anti-cancer mechanisms. Life Sci 2018; 207: 340-9.
[http://dx.doi.org/10.1016/j.lfs.2018.06.028] [PMID: 29959028]
[52]
Rege SD, Geetha T, Griffin GD, Broderick TL, Babu JR. Neuroprotective effects of resveratrol in Alzheimer disease pathology. Front Aging Neurosci 2014; 6: 218.
[http://dx.doi.org/10.3389/fnagi.2014.00218] [PMID: 25309423]
[53]
Jain S, Jain P, Umamaheshwari RB, Jain NK. Transfersomes--a novel vesicular carrier for enhanced transdermal delivery: Development, characterization, and performance evaluation. Drug Dev Ind Pharm 2003; 29(9): 1013-26.
[http://dx.doi.org/10.1081/DDC-120025458] [PMID: 14606665]
[54]
Tosato MG, Maya Girón JV, Martin AA, Krishna Tippavajhala V, Fernández Lorenzo de Mele M, Dicelio L. Comparative study of transdermal drug delivery systems of resveratrol: High efficiency of deformable liposomes. Mater Sci Eng C 2018; 90: 356-64.
[http://dx.doi.org/10.1016/j.msec.2018.04.073] [PMID: 29853101]
[55]
Bonechi C, Martini S, Ciani L, et al. Using liposomes as carriers for polyphenolic compounds: The case of trans-resveratrol. PLoS One 2012; 7(8): e41438.
[http://dx.doi.org/10.1371/journal.pone.0041438] [PMID: 22936976]
[56]
Park SN, Jo NR, Jeon SH. Chitosan-coated liposomes for enhanced skin permeation of resveratrol. Colloids Surf B Biointerfaces 2014; 20(4): 1481-5.
[57]
Scalia S, Trotta V, Iannuccelli V, Bianchi A. Enhancement of in vivo human skin penetration of resveratrol by chitosan-coated lipid mi-croparticles. Colloids Surf B Biointerfaces 2015; 135: 42-9.
[http://dx.doi.org/10.1016/j.colsurfb.2015.07.043] [PMID: 26241915]
[58]
Shringirishi M, Prajapati SK, Mahor A, Alok S, Yadav P, Verma A. Nanosponges: A potential nanocarrier for novel drug delivery-a re-view. Asian Pac J Trop Dis 2014; 4: S519-26.
[http://dx.doi.org/10.1016/S2222-1808(14)60667-8]
[59]
Pawar AY. Nanosponges: A novel drug delivery system. J Pharm Pharm Sci 2016; 10(04): 180-91.
[60]
Wen Q, Zhang Y, Luo J, et al. Therapeutic efficacy of thermosensitive Pluronic hydrogel for codelivery of resveratrol microspheres and cisplatin in the treatment of liver cancer ascites. Int J Pharm 2020; 582: 119334.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119334] [PMID: 32305362]
[61]
Ye F, Guo H, Zhang H, He X. Polymeric micelle-templated synthesis of hydroxyapatite hollow nanoparticles for a drug delivery system. Acta Biomater 2010; 6(6): 2212-8.
[http://dx.doi.org/10.1016/j.actbio.2009.12.014] [PMID: 20004747]
[62]
Washington KE, Kularatne RN, Biewer MC, Stefan MC. Combination loading of doxorubicin and resveratrol in polymeric micelles for increased loading efficiency and efficacy. ACS Biomater Sci Eng 2018; 4(3): 997-1004.
[http://dx.doi.org/10.1021/acsbiomaterials.7b00972] [PMID: 33418782]
[63]
Bonnefont-Rousselot D. Resveratrol and cardiovascular diseases. Nutrients 2016; 8(5): 250.
[http://dx.doi.org/10.3390/nu8050250] [PMID: 27144581]
[64]
Chalal M, Klinguer A, Echairi A, et al. Antimicrobial activity of resveratrol analogues. Molecules 2014; 19(6): 7679-88.
[http://dx.doi.org/10.3390/molecules19067679]
[65]
Zhou H-B, Chen J-J, Wang W-X, et al. Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol 2005; 11(2): 280-4.
[http://dx.doi.org/10.3748/wjg.v11.i2.280]
[66]
Sun W, Wang W, Kim J, et al. Anti-cancer effect of resveratrol is associated with induction of apoptosis via a mitochondrial pathway alignment. Adv Exp Med Biol 2008; 614: 179-86.
[http://dx.doi.org/10.1007/978-0-387-74911-2_21]
[67]
Xia N, Daiber A, Förstermann U, Li H. Antioxidant effects of resveratrol in the cardiovascular system. Br J Pharmacol 2017; 174(12): 1633-46.
[http://dx.doi.org/10.1111/bph.13492] [PMID: 27058985]
[68]
Abedini E, Khodadadi E, Zeinalzadeh E, et al. A comprehensive study on the antimicrobial properties of resveratrol as an alternative therapy. Int J Antimicrob Agents 2021; 2021: 8866311.
[http://dx.doi.org/10.1155/2021/8866311]
[69]
Vestergaard M, Ingmer H. Antibacterial and antifungal properties of resveratrol. Int J Antimicrob Agents 2019; 53(6): 716-23.
[http://dx.doi.org/10.1016/j.ijantimicag.2019.02.015] [PMID: 30825504]
[70]
Bishayee A. Cancer prevention and treatment with resveratrol: From rodent studies to clinical trials. Cancer Prev Res 2009; 2(5): 409-18.
[http://dx.doi.org/10.1158/1940-6207.CAPR-08-0160] [PMID: 19401532]
[71]
Turner RS, Thomas RG, Craft S, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology 2015; 85(16): 1383-91.
[http://dx.doi.org/10.1212/WNL.0000000000002035] [PMID: 26362286]
[72]
Agarwal B, Campen MJ, Channell MM, et al. Resveratrol for primary prevention of atherosclerosis: Clinical trial evidence for improved gene expression in vascular endothelium. Int J Cardiol 2013; 166(1): 246-8.
[http://dx.doi.org/10.1016/j.ijcard.2012.09.027] [PMID: 23098852]
[73]
Hoseini A, Namazi G, Farrokhian A, et al. The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. Food Funct 2019; 10(9): 6042-51.
[http://dx.doi.org/10.1039/C9FO01075K] [PMID: 31486447]
[74]
Fogacci F, Tocci G, Presta V, Fratter A, Borghi C, Cicero AFG. Effect of resveratrol on blood pressure: A systematic review and meta-analysis of randomized, controlled, clinical trials. Crit Rev Food Sci Nutr 2019; 59(10): 1605-18.
[http://dx.doi.org/10.1080/10408398.2017.1422480] [PMID: 29359958]
[75]
Haghighatdoost F, Hariri M. Can resveratrol supplement change inflammatory mediators? A systematic review and meta-analysis on randomized clinical trials. Eur J Clin Nutr 2019; 73(3): 345-55.
[http://dx.doi.org/10.1038/s41430-018-0253-4] [PMID: 30013206]
[76]
Öztürk E, Arslan AKK, Yerer MB, Bishayee A. Resveratrol and diabetes: A critical review of clinical studies. Biomed Pharmacother 2017; 95: 230-4.
[http://dx.doi.org/10.1016/j.biopha.2017.08.070] [PMID: 28843911]
[77]
Bradamante S, Barenghi L, Villa A. Cardiovascular protective effects of resveratrol. Cardiovasc Drug Rev 2004; 22(3): 169-88.
[http://dx.doi.org/10.1111/j.1527-3466.2004.tb00139.x] [PMID: 15492766]
[78]
Rafiee S, Mohammadi H, Ghavami A, Sadeghi E, Safari Z, Askari G. Efficacy of resveratrol supplementation in patients with nonalco-holic fatty liver disease: A systematic review and meta-analysis of clinical trials. J Gastrointestin Liver Dis 2021; 42: 101281.
[http://dx.doi.org/10.1016/j.ctcp.2020.101281] [PMID: 33321448]
[79]
Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. The therapeutic potential of resveratrol: A review of clinical trials. NPJ Precis Oncol 2017; 1(1): 1-9.
[http://dx.doi.org/10.1038/s41698-017-0038-6] [PMID: 28989978]
[80]
Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 1996; 85(10): 1017-25.
[http://dx.doi.org/10.1021/js950534b] [PMID: 8897265]
[81]
Caddeo C, Teskac K, Sinico C, Kristl J. Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells. Int J Pharm 2008; 363(1-2): 183-91.
[http://dx.doi.org/10.1016/j.ijpharm.2008.07.024] [PMID: 18718515]
[82]
Neves AR, Lúcio M, Martins S, Lima JL, Reis S. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int J Nanomedicine 2013; 8: 177-87.
[PMID: 23326193]
[83]
Ahmed RZ, Patil G, Zaheer Z. Nanosponges - a completely new nano-horizon: Pharmaceutical applications and recent advances. Drug Dev Ind Pharm 2013; 39(9): 1263-72.
[http://dx.doi.org/10.3109/03639045.2012.694610] [PMID: 22681585]
[84]
Selvamuthukumar S, Anandam S, Krishnamoorthy K, Rajappan M. Nanosponges: A novel class of drug delivery system--review. J Pharm Pharm Sci 2012; 15(1): 103-11.
[http://dx.doi.org/10.18433/J3K308] [PMID: 22365092]
[85]
Das S, Chaudhury A, Ng K-Y. Preparation and evaluation of zinc-pectin-chitosan composite particles for drug delivery to the colon: Role of chitosan in modifying in vitro and in vivo drug release. Int J Pharm 2011; 406(1-2): 11-20.
[http://dx.doi.org/10.1016/j.ijpharm.2010.12.015] [PMID: 21168477]
[86]
Das S, Ng K-Y. Impact of glutaraldehyde on in vivo colon-specific release of resveratrol from biodegradable pectin-based formulation. J Pharm Sci 2010; 99(12): 4903-16.
[http://dx.doi.org/10.1002/jps.22212] [PMID: 20572052]
[87]
López-Nicolás JM, Núñez-Delicado E, Pérez-López AJ, Barrachina AC, Cuadra-Crespo P. Determination of stoichiometric coefficients and apparent formation constants for β-cyclodextrin complexes of trans-resveratrol using reversed-phase liquid chromatography. J Chromatogr A 2006; 1135(2): 158-65.
[http://dx.doi.org/10.1016/j.chroma.2006.09.013] [PMID: 17083948]
[88]
Lucas-Abellán C, Fortea I, López-Nicolás JM, Núñez-Delicado E. Cyclodextrins as resveratrol carrier system. Food Chem 2007; 104(1): 39-44.
[http://dx.doi.org/10.1016/j.foodchem.2006.10.068]
[89]
Lu Z, Cheng B, Hu Y, Zhang Y, Zou G. Complexation of resveratrol with cyclodextrins: Solubility and antioxidant activity. Food Chem 2009; 113(1): 17-20.
[http://dx.doi.org/10.1016/j.foodchem.2008.04.042]
[90]
Chen WM, Shaw LH, Chang PJ, et al. Hepatoprotective effect of resveratrol against ethanol-induced oxidative stress through induction of superoxide dismutase in vivo and in vitro. Exp Ther Med 2016; 11(4): 1231-8.
[http://dx.doi.org/10.3892/etm.2016.3077] [PMID: 27073428]
[91]
Rafieian-Kopaei M, Baradaran A. Combination of metformin with other antioxidants may increase its renoprotective efficacy. J Renal Inj Prev 2013; 2(2): 35-6.
[PMID: 25340122]

Rights & Permissions Print Cite
Article Metrics
23
1
© 2024 Bentham Science Publishers | Privacy Policy